Stealth Peptides Inc.' Bendavia(TM) Recognized as One of Stealth Peptides Inc.'s Top 10 Cardiovascular and Metabolic Development Programs to Watch
11/8/2010 9:53:39 AM
BOSTON--(BUSINESS WIRE)--Stealth Peptides, a privately held biopharmaceutical company developing innovative mitochondrial therapies for diseases with significant unmet medical needs, announced today that its lead clinical candidate, Bendavia™, a novel compound that targets the mitochondrion to treat ischemia reperfusion injury, was recognized as one of the “Top 10” cardiovascular and metabolic projects to watch by Windhover Information, a division of Elsevier Business Intelligence. Stealth presented an overview of Bendavia and its potential for treating cardio–renal diseases during Windhover’s recent Therapeutic Area Partnerships Conference in Boston, Massachusetts.
comments powered by